Board of Directors
Peter has a wealth of experience and has held key senior positions, including Chairman, CEO and CFO in a number of companies in the healthcare industry, and played a significant role in their growth.
Peter spent 12 years at Celltech Group plc (1992–2004) as CFO and Deputy CEO, six years at ProStaken Group plc as Chairman (2007–2013) and interim CEO (2010–2011) and three years as Chairman of Proximagen plc (2009-2012).
Peter is currently Chairman of Abcam plc, Advanced Medical Solutions Plc and Diurnal Plc and Non-Executive Director of Oxford Nanopore Technologies Ltd and Istesso Ltd.
The Board is satisfied that these external appointments do not impact upon the Chairman's ability to discharge his role at the Company effectively.
Shaun is the Chief Executive Officer of the Clinigen Group and has the responsibility for the Group achieving its key performance indicators and plays a central role in setting the Group strategy.
Shaun has played a pivotal role in the development of Clinigen, joining the company in January 2012 as Chief Operating Officer, when it was a privately owned company with a turnover of £82m.
He was a key part of the executive team that took Clinigen through IPO in September 2012. Then as deputy CEO in 2015 and CEO from November 2016, has been a fundamental part of the leadership of the impressive strategic growth of the company from £135m market capitalisation in 2012 to its current position as one of the largest companies on AIM on the London Stock Exchange.
In 2017, Shaun oversaw the largest M&A healthcare deal of the year in the UK with the successful acquisition of Quantum, in addition to acquiring the largest supplier of unlicensed medicines in Japan, IMMC.
Shaun was awarded the Entrepreneur of the Year Healthcare (Western Europe) in 2017 and 2018 by the European CEO Awards.
Prior to joining Clinigen, Shaun held senior global strategic, commercial and operational roles at Pfizer, Sanofi, Wolters Kluwer Health and the KnowledgePoint360 Group (now part of UDG Healthcare).
Martin joined Clinigen in August 2015 and has over 19 years’ experience working for international, listed companies.
Before Clinigen, Martin worked for Hays plc, Europe’s largest professional recruitment business. He began there as Head of Investor Relations and M&A before becoming Finance Director for the Continental Europe and Rest of World division, which operated across 21 countries with revenues of over £1bn. Prior to that, Martin held several financial roles at the FTSE 100 logistics group, Exel plc (now part of Deutsche Post), including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.
John has over 30 years’ experience as a corporate lawyer, dealing with corporate finance and commercial contract issues across a number of industries. He was formerly Managing Partner at Ricksons LLP and subsequently became a Partner at DWF LLP.
John is currently the Chairman of the Board of Enigma Group Holdings Ltd.
Ian has considerable experience as both an Executive Director and as a Non-Executive Director. Ian is CEO of F2G Limited.
Ian currently holds positions as Non-Executive Director of Consort Medical plc and Bioventix plc, where he is the Non-Executive Chairman. Ian is also Chairman of the Investment Committee at Cancer Research UK Pioneer Fund, Director of Casewell Consulting Ltd, F2G Ltd, and Wells Stores Ltd, and an Operating Partner at Advent Life Sciences LLP.
Anne has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies.
Anne is a Chartered Accountant (FCA), and Corporate Tax Adviser (CTA – AITI) and holds a degree in Business studies from Trinity College, Dublin. Anne's previous roles include CFO of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc. Prior to her role at Vectura, Anne held a number of senior finance positions at Celltech Group plc, Medeva plc and KPMG.
Anne is CFO of Kymab Ltd a private biopharmaceutical company. She is also a Non-Executive Director of Elementis plc, a FTSE-250 global specialty chemicals company.
Professor Boyd has accumulated over 30 years extensive medical and policy experience within the pharmaceutical sector, holding senior roles within some of the world’s largest pharmaceutical companies.
He began his pharmaceutical career with Glaxo Group Research Ltd. From 1988, he led ICI’s cardiovascular medical research team, and later assumed the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada.
In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones.
In 2005, Professor Boyd left to set up Boyd Consultants, to focus on aiding and supporting early stage life-science based companies in Europe, North America and Japan.
Professor Boyd is a graduate in Biochemistry and Medicine from the University of Birmingham and is currently a Fellow, and past Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK. He was elected President of Faculty in November 2015 to November 2018, following three years as Vice-President. Whilst as President he was also a Council Member of both the Royal College of Physicians, London and the Academy of Medical Royal Colleges, UK.
In November 2009, Professor Boyd was appointed an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School, in recognition of his expertise in medicines development. He was also elected as a Fellow of the Royal College of Physicians, London in April 2018.
Professor Boyd is currently CEO of Boyd Consultants Ltd, a private specialist biopharmaceutical consultancy company. He is also a Director of BaxterBoyd Ltd and Celentyx Ltd.